Suppr超能文献

帕金森病认知障碍患者同意接受医学治疗的能力

Competency to consent to medical treatment in cognitively impaired patients with Parkinson's disease.

作者信息

Dymek M P, Atchison P, Harrell L, Marson D C

机构信息

Department of Psychiatry, University of Chicago, IL, USA.

出版信息

Neurology. 2001 Jan 9;56(1):17-24. doi: 10.1212/wnl.56.1.17.

Abstract

OBJECTIVES

To investigate capacity to consent to medical treatment (competency) in cognitively impaired patients with PD.

BACKGROUND

Although competency has been studied empirically in patients with cortical dementia (AD), no empirical studies have examined competency in patients with PD or other subcortical neurodegenerative disorders.

METHODS

Patients with PD with cognitive impairment (n = 20) and older controls (n = 20) were compared using a standardized competency measure (Capacity to Consent to Treatment Instrument [CCTI]) and neuropsychological test measures. The CCTI tests competency performance and assigns outcomes (capable, marginally capable, incapable) under four different legal standards (LS).

RESULTS

Patients with PD performed below controls on the four LS: capacity to evidence a treatment choice (LS1) (p < 0.03), capacity to appreciate consequences of a treatment choice (LS3) (p < 0.03), capacity to provide rational reasons for a treatment choice (LS4) (p < 0.0001), and capacity to understand the treatment situation and choices (LS5) (p < 0.0001). With respect to competency outcomes, patients with PD demonstrated increasing compromise (marginally capable or incapable outcomes) across the four standards: LS1 (25%), LS3 (45%), LS4 (55%), and LS5 (80%). In the PD group, simple measures of executive function (the Executive Interview) and to a lesser extent memory/orientation (Dementia Rating Scale, Memory subscale) were key predictors of competency performance and outcome on the LS.

CONCLUSIONS

Cognitively impaired patients with PD are likely to have impaired consent capacity, and are at risk of losing competency over the course of their neurodegenerative illness. Patients with PD have particular difficulty meeting more stringent, clinically relevant competency standards that tap reasoning skills and comprehension of treatment information. Executive dysfunction appears to be a primary neurocognitive mechanism for competency loss in PD.

摘要

目的

研究帕金森病(PD)认知障碍患者对医疗治疗的同意能力(行为能力)。

背景

尽管已对皮质性痴呆(AD)患者的行为能力进行了实证研究,但尚无实证研究考察PD患者或其他皮质下神经退行性疾病患者的行为能力。

方法

使用标准化行为能力测量工具(治疗同意能力量表 [CCTI])和神经心理学测试方法,对20例伴有认知障碍的PD患者和20例老年对照者进行比较。CCTI在四种不同法律标准(LS)下测试行为能力表现并给出结果(有行为能力、勉强有行为能力、无行为能力)。

结果

在四种法律标准下,PD患者的表现均低于对照者:证明治疗选择的能力(LS1)(p < 0.03)、认识到治疗选择后果的能力(LS3)(p < 0.03)、为治疗选择提供合理理由的能力(LS4)(p < 0.0001)以及理解治疗情况和选择的能力(LS5)(p < 0.0001)。关于行为能力结果,PD患者在四种标准下表现出越来越多的行为能力受损(勉强有行为能力或无行为能力结果):LS1(25%)、LS3(45%)、LS4(55%)和LS5(80%)。在PD组中,执行功能的简单测量指标(执行访谈)以及程度较轻的记忆/定向指标(痴呆评定量表,记忆分量表)是法律标准下行为能力表现和结果的关键预测因素。

结论

伴有认知障碍的PD患者可能同意能力受损,并且在神经退行性疾病过程中有失去行为能力的风险。PD患者在满足更严格的、与临床相关的行为能力标准方面特别困难,这些标准涉及推理技能和对治疗信息的理解。执行功能障碍似乎是PD患者行为能力丧失的主要神经认知机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验